MTEM
Molecular Templates Inc (MTEM)
$0.91
Key Stats
$0.9001
Day's Range
$0.969
$0.7649
52-Week Range
$8.29
| Returns | |
| 1 month return | 1.14% |
| 3 month return | 71.36% |
| 1 year return | 87.22% |
| 5 year return | 95.42% |
Company Information
Molecular Templates is a clinical-stage company focused on the discovery and development of targeted biologic therapeutics. Its proprietary drug platform technology, known as engineered toxin bodies, or ETBs, leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer and other serious diseases.
| Organization | Molecular Templates Inc |
| Employees | 239 |
| CEO | Eric Poma |
| Industry | Health Technology |
Analyst Recommendation
based on 14 analysts ratings
Buy
92%
Buy
7%
Hold
0%
Sell
Based on 14 Wall street analysts offering stock ratings for Molecular Templates Inc(by analysts ranked 0 to 5 stars)
Recommendation Trend
Based on 14 analyst
| Current | 1M Ago | 3M Ago | |
| Buy | 13 | 13 | 13 |
| Hold | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 |
| Consensus | BUY | BUY | BUY |
Company Financials
Highlights
| Market Capitalization | 101.9M |
| Book Value | 1.17 |
| Dividend Share | 0.0 |
| Dividend Yield | 0.0 |
| Earnings Share | -1.5 |
| PEG Ratio | 0.0 |
| Wall Street Target Price | 10.92 |
Valuation
| Trailing PE | 0.0 |
| Forward PE | 0.0 |
| Price/Sales (ttm) | 2.63 |
| Price/Book (mrq) | 1.66 |
| Enterprise Value | 13.3M |
| Enterprise Value/Revenue | 0.34 |
| Enterprise Value/Ebitda | 0.0 |
Technicals
| Beta | 1.26 |
| 50 Day MA | 2.62 |
| 200 Day MA | 4.67 |
Institutional Holdings
Bellevue Group AG
19.66%
Bvf Inc
7.18%
BlackRock Inc
5.06%
Vanguard Group Inc
4.63%
Caxton Corp
3.64%
FRAZIER MANAGEMENT LLC
2.44%
